TABLE 6.
MSRSGC Diagnostic Categories and Their Corresponding Risks of Malignancy in Previous Studies
| Source | No. | No.a | Risk of Malignancy, % | Sensitivity | Specificity | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | II | III | IVa | IVb | V | VI | |||||
| Viswanathan 20185 | 627 | 373 | 6.7 | 7.1 | 38.9 | 5 | 34.2 | 92.9 | 92.3 | 79.0 | 98 |
| Savant 20196 | 199 | 199 | 0 | 0 | 33 | 0.8 | 40.9 | 100 | 100 | — | — |
| Dubucs 20197 | 328 | 216 | 34 | 0 | 0 | 3.1 | 45.5 | 68.8 | 100 | — | — |
| Mazzola 20198 | 375 | 366 | 19 | 11.8 | 25 | 5.5 | 50 | 71.4 | 94.6 | — | — |
| Wu 20199 | 1560 | 694 | 18.3 | 8.9 | 37.5 | 2.9 | 40.7 | 100 | 98.3 | 89 | 99 |
| Song 201910 | 893 | 429 | 16.1 | 17.9 | 30.6 | 2.2 | 46.6 | 78.9 | 98.5 | — | — |
| Choy 201911 | 376 | 376 | 14.5 | 26.7 | 29.3 | 2.7 | 19.1 | 87.5 | 100 | — | — |
| Chen 201912 | 1020 | 349 | 8.6 | 15.4 | 36.8 | 2.6 | 32.3 | 71.4 | 100 | 70.4 | 99.2 |
| Lee 201913 | 1384 | 421 | 10 | 17.5 | 29.5 | 0.5 | 17.1 | 83.3 | 100 | 76.5 | 99.1 |
| Mazzola 202014 | 503 | 503 | 19.5 | 14.3 | 17.6 | 3.6 | 24.6 | 66.7 | 96.8 | — | — |
| Total b | 6889 | 3550 | 14.1 | 12.7 | 31.6 | 2.7 | 34.8 | 80 | 97.5 | — | — |
| Current study | 12,898 | 12,898 | 12.5 | 10.3 | 29 | 2.3 | 28.6 | 83 | 99.3 | 81.2 | 99.1 |
| MSRSGC classification | — | — | 25 | 10 | 20 | <5 | 35 | 60 | 90 | — | — |
Abbreviation: MSRSGC, Milan System for Reporting Salivary Gland Cytopathology.
a
Histopathologically correlated fine‐needle aspiration cytology.
b
Choy et al's study11 is not part of the total calculation because of the unavailability of their MSRSGC distribution rates.